Interethnic differences in drug response: The contribution of genetic variability in β adrenergic receptor and cytochrome P4502C9

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 2, 2007, Pages 215-218

  Muszkat, M ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C9; WARFARIN;

CLINICAL PRACTICE; DRUG METABOLISM; DRUG RESPONSE; ETHNIC DIFFERENCE; ETHNICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC;

EID: 34447564024     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100142     Document Type: Review

References (30)

1. Stein, C.M., Lang, C.C., Xie, H.G. & Wood, A.J. Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics 11, 95-110 (2001).
2. Small, K.M., McGraw, D.W. & Liggett, S.B. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43, 381-411 (2003).
3. Xie, H.G., Kim, R.B., Wood, A.J. & Stein, C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
4. Hinds, D.A. et al. Whole-genome patterns of common DNA variation in three human populations. Science 307, 1072-1079 (2005).
5. Wilson, J.F. et al. Population genetic structure of variable drug response. Nat. Genet. 29, 265-269 (2001).
6. Keita, S.O. et al. Conceptualizing human variation. Nat. Genet. 36(Suppl 11), S17-S20 (2004).
7. Materson, B.J. et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328, 914-921 (1993).
8. Brewster, L.M., van Montfrans, G.A. & Kleijnen, J. Systematic review: antihypertensive drug therapy in black patients. Ann. Intern. Med. 141, 614-627 (2004).
9. Wood, A.J. & Zhou, H.H. Ethnic differences in drug disposition and responsiveness. Clin. Pharmacokinet. 20, 350-373 (1991).
10. Zhou, H.H., Koshakji, R.P., Silberstein, D.J., Wilkinson, G.R. & Wood, A.J. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N. Engl. J. Med. 320, 565-570 (1989).
11. Bruck, H. et al. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J. Am. Coll. Cardiol. 46, 2111-2115 (2005).
12. Sofowora, G.G. et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin. Pharmacol. Ther. 73, 366-371 (2003).
13. Johnson, J.A., Zineh, I., Puckett, B.J., McGorray, S.P., Yarandi, H.N. & Pauly, D.F. Beta1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74, 44-52 (2003).
14. White, H.L., et al. & MERIT-HF Study Group An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart. Fail. 5, 463-468 (2003).
15. de Groote, P. et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet. Genomics 15, 137-142 (2005).
16. Perez, J.M. et al. Beta1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 9, 1300-1305 (2003).
17. Terra, S.G. et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet. Genomics 15, 227-234 (2005).
18. Liggett, S.B. et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc. Natl. Acad. Sci. USA. 103, 11288-11293 (2006).
19. Dishy, V. et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035 (2001).
20. Bruck, H. et al. The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. Pharmacogenetics 13, 59-66 (2003).
21. Kaye, D.M., Smirk, B., Williams, C., Jennings, G., Esler, M. & Holst, D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13, 379-382 (2003).
22. Lanfear, D.E., Jones, P.G., Marsh, S., Cresci, S., McLeod, H.L. & Spertus, J.A. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 294, 1526-1533 (2005).
23. Kirchheiner, J. & Brockmoller, J. Review. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16 (2005).
24. Scordo, M.G., Pengo, V., Spina, E., Dahl, M.L., Gusella, M. & Padrini, R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72, 702-710 (2002).
25. Aithal, G.P., Day, C.P., Kesteven, P.J. & Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
26. Lindh, J.D., Lundgren, S., Holm, L., Alfredsson, L. & Rane, A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. 78, 540-550 (2005).
27. Takahashi, H. et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263 (2003).
28. Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
29. Veenstra, D.L. et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
30. Loebstein, R. et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77, 365-372 (2005).